drug · small molecule

NEXLIZET

updated 3mo ago

by $ESPR Esperion Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

ATP-citrate synthase

all catalysts(0)

nothing on the calendar yet

Trials studying NEXLIZET

—A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemiarecruitingn=2,000
phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Eventsnot yet recruitingn=103
phase3A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acidnot yet recruitingn=222
—A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemiaactive not recruitingn=2,560
phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)completedn=301
—Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemiaactive not recruitingn=5,000
phase1Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatincompletedn=58
phase3A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemiacompletedn=130

more trials →

News(2)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 29d ago

brand

NEXLIZET

trade names

Bempedoic acid component of nexlizet, Nexletol, Nilemdo

generic

BEMPEDOIC ACID

MOA

12.1 Mechanism of Action NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine. Bempedoic acid Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.

indication

1 INDICATIONS AND USAGE NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). NEXLIZET, a combination of bempedoic acid, an adenosine triphosphate citrate lyase (ACL) inhibitor, and ezetimibe, a dietary cholesterol absorption inhibitor, is indicated: As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 ) Bempedoic acid, a component of NEXLIZET, is indicated: To reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 33m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

NEXLIZET

updated 3mo ago

by $ESPR Esperion Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

ATP-citrate synthase

all catalysts(0)

nothing on the calendar yet

Trials studying NEXLIZET

—A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemiarecruitingn=2,000
phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Eventsnot yet recruitingn=103
phase3A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acidnot yet recruitingn=222
—A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemiaactive not recruitingn=2,560
phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)completedn=301
—Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemiaactive not recruitingn=5,000
phase1Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatincompletedn=58
phase3A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemiacompletedn=130

more trials →

News(2)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 29d ago

brand

NEXLIZET

trade names

Bempedoic acid component of nexlizet, Nexletol, Nilemdo

generic

BEMPEDOIC ACID

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 33m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

NEXLIZET

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying NEXLIZET

News(2)

Report a data issue

comments(0)

NEXLIZET

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying NEXLIZET

News(2)

Report a data issue

comments(0)